ArticleESMO open2026
Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundFibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression is an emerging biomarker and a potential therapeutic target in gastric and gastroesophageal junction cancers (G/GEJC). Limited data exist on the global prevalence of FGFR2b overexpression in advanced G/GEJC using a validated assay. We assessed the prevalence of FGFR2b protein overexpression in a pooled analysis of tumor samples collected as part of the prescreening process for two global phase III studies of bemarituzumab as first-line treatment for locally advanced or metastatic G/GEJC. MATERIALS AND
methodsAs of 20 February 2025, 7910 tumor samples from patients prescreened for enrollment in the FORTITUDE-101 (NCT05052801; n = 3752) and FORTITUDE-102 (NCT05111626; n = 4158) studies were centrally tested for FGFR2b protein overexpression by immunohistochemistry (IHC) and had evaluable results. FGFR2b overexpression was defined as both any percentage (>0%) of tumor cells (TCs) and ≥10% of TCs exhibiting moderate (2+) to strong (3+) membrane staining of FGFR2b. Prevalence was analyzed across defined patient and sample characteristics.
resultsThe estimated prevalence of FGFR2b any 2+/3+ was 36.5% [95% confidence interval (CI) 35.4-37.6; 2887/7910] and that of FGFR2b ≥10% 2+/3+ was 16.6% (95% CI 15.7-17.4; 1310/7910). Prevalence estimates from this pooled analysis and a separate analysis for FORTITUDE-102 [any 2+/3+: 35.8% (95% CI 34.3-37.2); FGFR2b ≥10% 2+/3+: 17.3% (95% CI 16.1-18.4)] were consistent with results previously reported for FORTITUDE-101 (Rha SY, Zhang Y, Elme A, et al. Prevalence of FGFR2b protein overexpression in advanced gastric cancers during prescreening for the phase III FORTITUDE-101 trial. JCO Precis Oncol. 2025;9:e2400710). FGFR2b prevalence was consistent across patient and sample characteristics [age, sex, collection method (biopsy versus resection), collection site, location of primary tumor, and geographic region].
conclusionThis study represents the largest prevalence assessment of FGFR2b overexpression in G/GEJC using a validated IHC assay. The observed estimates of 36.5% (any 2+/3+) and 16.6% (FGFR2b ≥10% 2+/3+) suggest that FGFR2b is prevalent in a meaningful proportion of patients with advanced G/GEJC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.